Riliprubart Prefilled Pen (PFP)
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polyneuropathy, Inflammatory Demyelinating, Chronic
Conditions
Polyneuropathy, Inflammatory Demyelinating, Chronic
Trial Timeline
Apr 1, 2025 → Oct 3, 2029
NCT ID
NCT06859099About Riliprubart Prefilled Pen (PFP)
Riliprubart Prefilled Pen (PFP) is a phase 3 stage product being developed by Sanofi for Polyneuropathy, Inflammatory Demyelinating, Chronic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06859099. Target conditions include Polyneuropathy, Inflammatory Demyelinating, Chronic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06859099 | Phase 3 | Recruiting |
Competing Products
20 competing products in Polyneuropathy, Inflammatory Demyelinating, Chronic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Qutenza + Pregabalin | Astellas Pharma | Approved | 85 |
| Ranirestat + Placebo | Eisai | Phase 2/3 | 65 |
| KITE-363 + Fludarabine + Cyclophosphamide | Gilead Sciences | Phase 1 | 32 |
| Fx-1006A + Placebo | Pfizer | Phase 2/3 | 64 |
| tafamidis meglumine | Pfizer | Approved | 84 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| Vyndaqel | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Phase 3 | 76 |
| Imipramine + Pregabalin + Imipramine, pregabalin + Placebo | Pfizer | Approved | 84 |
| Fx-1006A | Pfizer | Phase 2/3 | 64 |
| riliprubart + Placebo + riliprubart + Placebo + IVIg + Placebo | Sanofi | Phase 3 | 76 |
| Intravenous Immunoglobulin | CSL | Pre-clinical | 22 |
| IgPro10 | CSL | Approved | 84 |
| Immune Globulin Subcutaneous (Human) | CSL | Pre-clinical | 22 |
| IgPro20 | CSL | Phase 3 | 76 |
| Hizentra | CSL | Pre-clinical | 22 |
| 10% liquid formulation of human immunoglobulin | CSL | Phase 3 | 76 |
| IgPro20 (low dose) + Placebo + IgPro10 + IgPro20 (high dose) | CSL | Phase 3 | 76 |
| levetiracetam | UCB | Phase 2 | 49 |
| Rozanolixizumab | UCB | Pre-clinical | 20 |